05:02 PM EDT, 07/01/2024 (MT Newswires) -- Arcturus Therapeutics Holdings ( ARCT ) said late Monday enrollment of eight subjects was completed for the phase 2 study in the European Union and the UK completed enrollment of ARCT-810, an investigational mRNA therapeutic to treat ornithine transcarbamylase deficiency,

The subjects include adolescents and adults at the 0.3 milligrams per kilogram dose level.

The clinical program is being expanded in the US by enrolling patients with more severe disease, and phase 2 is expected to be completed in the US with interim data will be provided later this year, the company said.

The company also plans to submit an investigative new drug application in the next 60 days for a phase 2 multiple ascending dose study for ARCT-032, an inhaled mRNA therapeutic to treat cystic fibrosis.

Price: 23.29, Change: -0.37, Percent Change: -1.56